Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 8/20 | 0.56 |
| ▸ | TAS1R1 | Q7RTX1 | 8/20 | 0.56 |
| ▸ | CA2 | P00918 | 3/20 | 0.54 |
| ▸ | APP | P05067 | 2/20 | 0.53 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | CA3 | P07451 | 1/20 | 0.48 |
| ▸ | CA6 | P23280 | 1/20 | 0.48 |
| ▸ | CA5A | P35218 | 1/20 | 0.48 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20559453 | 1.00 | TAS1R3 (0.56) | TAS1R3TAS1R1CA2APPCYP2A6 | |
| Hydrochloric Acid SCHEMBL10458712 | 0.98 | TAS1R3 (0.55) | TAS1R3TAS1R1CA2APPCYP2A6 | |
| SCHEMBL10460824 | 0.86 | CA2 (0.54) | CA2APPCYP2A6CA12CA1 | |
| SCHEMBL12301434 | 0.86 | CYP2A6 (0.54) | TAS1R3TAS1R1CA2APPCYP2A6 | |
| SCHEMBL1391306 | 0.84 | MAOA (0.46) | TAS1R3TAS1R1 | |
| SCHEMBL7922363 | 0.83 | TAS1R3 (0.52) | TAS1R3TAS1R1CA2APPCYP2A6 | |
| SCHEMBL9827175 | 0.82 | CA12 (0.45) | TAS1R3TAS1R1CA12CA1CA9 | |
| SCHEMBL12086935 | 0.82 | CA2 (0.50) | TAS1R3TAS1R1CA2APPCYP2A6 | |
| SCHEMBL12310840 | 0.80 | TAS1R3 (0.50) | TAS1R3TAS1R1CA2APPCYP2A6 | |
| SCHEMBL10962309 | 0.78 | ADRA2A (0.53) | TAS1R3TAS1R1CA2APPCYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11420944-B2 | Voltage-dependent t-type calcium channel blocker | NIPPON CHEMIPHAR CO., LTD. (JP) | 2022-08-23 | — | — | US | disclosed |
| US-20190077767-A1 | VOLTAGE-DEPENDENT T-TYPE CALCIUM CHANNEL BLOCKER | NIPPON CHEMIPHAR CO., LTD. (JP) | 2019-03-14 | — | — | US | disclosed |
| EP-3404021-A1 | VOLTAGE-DEPENDENT T-TYPE CALCIUM CHANNEL INHIBITOR | Nippon Chemiphar Co., Ltd. (JP) | 2018-11-21 | — | — | EP | disclosed |
| EP-0283522-B1 | TRIAZINE DERIVATIVE, PRODUCTION THEREOF, AND HERBICIDE CONTAINING SAME AS EFFECTIVE INGREDIENT | IDEMITSU KOSAN COMPANY LIMITED (JP) | 1991-02-27 | — | — | EP | disclosed |
| US-4932998-A | LOW PHYTOTOXICITY FOR PADDY RICE PLANTS | IDEMITSU KOSAN COMPANY LIMITED (JP) | 1990-06-12 | — | — | US | disclosed |
| EP-0283522-A1 | TRIAZINE DERIVATIVE, PRODUCTION THEREOF, AND HERBICIDE CONTAINING SAME AS EFFECTIVE INGREDIENT | IDEMITSU KOSAN COMPANY LIMITED (JP) | 1988-09-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11420944-B2 | Voltage-dependent t-type calcium channel blocker | CACNA1I, CACNA1G, CACNA1E | TAS1R3 944/4885TAS1R1 1296/4885CA2 99/4885 |
| US-20190077767-A1 | VOLTAGE-DEPENDENT T-TYPE CALCIUM CHANNEL BLOCKER | CACNA1I, CACNA1G, CACNA1E | TAS1R3 861/4885TAS1R1 1168/4885CA2 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.